Boston, MA – Sai Life Sciences, a leading global contract research, development, and manufacturing organization (CRDMO), recently convened its highly…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning market for obesity treatments, propelled recently by the widespread adoption of GLP-1 receptor agonists, stands at a critical…
Read More
Immuto Scientific Pioneers AI-Enhanced Mass Spectrometry for Unprecedented Protein Structure Throughput
Immuto Scientific, a company co-founded in 2018 by CEO Faraz A. Choudhury, Ph.D., and CTO Daniel Benjamin, Ph.D., both electrical…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
The landscape of drug discovery and development is witnessing a significant resurgence in covalent inhibitors, a class of therapeutics that…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
The pharmaceutical industry, known for its dynamic shifts and competitive landscape, has witnessed a seismic change at its pinnacle. Eli…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
The core of Amazon Bio Discovery lies in its ability to route AI-designed antibody candidates directly to leading DNA Synthesis…
Read More
OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…
Read More
Sai Life Sciences Plans to Recruit 700+ Professionals in FY27 as Indian CRDMO Demand Accelerates
Hyderabad, India – Sai Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced an ambitious…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, announced a landmark collaboration with pharmaceutical giant Eli…
Read More
